A targeted resequencing gene panel for focal epilepsy
Michael S Hildebrand1, Candace T Myers1, Gemma L Carvill1
1From the Epilepsy Research Centre (M.S.H., B.M.R., J.A.D., S.A.M., M.R.N., I.E.S., S.F.B.), Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia; Division of Genetic Medicine (C.T.M., G.L.C., H.C.M.), Department of Pediatrics, University of Washington, Seattle, WA; Florey Institute for Neuroscience and Mental Health (U.N., E.V.G., C.J.M., C.A.R., S.P., I.E.S.), University of Melbourne, Melbourne, Victoria, Australia; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia; and Department of Pediatrics (I.E.S.), University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia.
A new gene panel effectively detects mutations in focal epilepsy cases. This molecular inversion probe (MIP) technology offers a sensitive, cost-effective approach for genetic screening in epilepsy research.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Focal epilepsy is the most common epilepsy phenotype.
- Genetic factors play a significant role in epilepsy etiology.
- Identifying causative genes is crucial for diagnosis and treatment.
Purpose of the Study:
- To develop and validate a targeted resequencing gene panel for focal epilepsy.
- To apply molecular inversion probe (MIP) technology for enhanced genetic analysis.
- To investigate the genetic basis of unsolved focal epilepsy cases.
Main Methods:
- Designed a targeted resequencing gene panel using MIP capture technology.
- Performed massively parallel sequencing on the Illumina platform.
- Analyzed germline and somatic mutations in 251 patients with focal epilepsy.
Main Results:
- Successfully detected mutations in 4 previously genotyped focal epilepsy cases.
- Identified 11 novel or rare missense variants in 5 genes (CHRNA4, GRIN2B, KCNT1, PCDH19, SCN1A).
- Two variants were predicted pathogenic, explaining ~0.8% of the cohort; 8 were of uncertain significance.
Conclusions:
- Developed and validated a sensitive, efficient, and cost-effective gene panel for focal epilepsies.
- MIP technology provides an advantageous approach for large-scale genetic screening.
- Current known gene mutations explain a small fraction of focal epilepsy cases, highlighting the need for further gene discovery.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
